Melanoma

>

Latest News

Phase 2 SCOPE Trial of SCIB1 Achieves Positive ORR in Advanced Melanoma
Phase 2 SCOPE Trial of SCIB1 Achieves Positive ORR in Advanced Melanoma

September 21st 2023

Positive objective response results were demonstrated in the first stage of the phase 2 SCOPE trial. Now, 27 additional patients with advanced melanoma will be treated with SCIB1 and checkpoint inhibitors in stage 2.

FDA Pushes Back Decision on Lifileucel for Advanced Melanoma Treatment
FDA Pushes Back Decision on Lifileucel for Advanced Melanoma Treatment

September 15th 2023

Role of Tolerability in Using Immunotherapy for Metastatic Melanoma
Role of Tolerability in Using Immunotherapy for Metastatic Melanoma

September 12th 2023

Neoadjuvant Immunotherapy for Stage III Melanoma Emerges as New Standard of Care
Neoadjuvant Immunotherapy for Stage III Melanoma Emerges as New Standard of Care

August 28th 2023

COMBO300 Shows Benefit Without Severe Toxicity in Advanced BRAF V600+ Melanoma
COMBO300 Shows Benefit Without Severe Toxicity in Advanced BRAF V600+ Melanoma

August 21st 2023

Video Series
Video Interviews
Podcasts

More News